Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 28Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 17Pancreatic Neoplasms 11Glioblastoma 11Melanoma 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 10Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Urinary Bladder Neoplasms 7Neoplasm Metastasis 7Colonic Neoplasms 7Brenner Tumor 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Prostatic Neoplasms 6Mycosis Fungoides 6Leukemia, Lymphocytic, Chronic, B-Cell 6Brain Neoplasms 6Triple Negative Breast Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4

Interventions

Standard of Care 8Surveys and Questionnaires 7COVID-19 Vaccines 6Blood Specimen Collection 6BNT162 Vaccine 6Specimen Handling 52019-nCoV Vaccine mRNA-1273 5Hydroxychloroquine 4Surgical Procedures, Operative 3Practice Guidelines as Topic 3tocilizumab 2sotrovimab 2sinovac COVID-19 vaccine 2cilgavimab and tixagevimab drug combination 2Sodium Chloride 2Pandemic Preparedness 2Data Collection 2CVnCoV COVID-19 vaccine 2COH04S1 COVID-19 vaccine 2Azithromycin 2selinexor 1remdesivir 1regorafenib 1proxalutamide 1palbociclib 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
COVID-19 × Disulfides × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡